The epsilon 2 and 4 alleles of apolipoprotein E and ischemic vascular events in the greek population - Implications for the interpretation of similar studies

Angiology

Volumn 54, Issue 1, 2003, Pages 51-58

  Kolovou, Genovefa D ^a   Daskalova, Deliana Ch ^a   Hatzivassiliou, Marilena ^b   Yiannakouris, Nikos ^c   Pilatis, Nektarios D ^a   Elisaf, Moses ^d   Mikhailidis, Dimitri P ^e   Cariolou, Marios A ^b   Cokkinos, Dennis V ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^c HAROKOPIO UNIVERSITY   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ADULT; ALLELE; ANGIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENOTYPE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PROTEIN POLYMORPHISM; RISK FACTOR;

EID: 0037277143     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970305400107     Document Type: Article

References (49)

1. Faber B, Cleutjens K, Niessen R, et al. Identification of genes potentially involved in rupture of human atherosclerotic plaques. Circ Res 89:547-554, 2001.
2. Davignon J, Cohn JS, Mabile L, et al: Apolipoprotein E and atherosclerosis: Insight from animal and human studies. Clin Chim Acta 286:115-143, 1999.
3. Utermann G, Hardewig A, Zimmer F: Apolipoprotein E phenotypes in patients with myocardial infarction. Hum Genet 65:237-241, 1984.
4. Wilson PWF, Myers RH, Larson MG, et al: Apolipoprotein E alleles, dyslipidemias and coronary heart disease: The Framingham Offspring Study. JAMA 272:1666-1671, 1994.
5. Kolovou G, Yiannakouris N, Malakos J, et al: Association of apolipoprotein E polymorphism with myocardial infarction in Greek patients. Curr Med Res Opin 18:118-124, 2002.
6. Kervinen K, Sodervik H, Makela J, et al: Is the development of adenoma and carcinoma in proximal colon related to apolipoprotein E phenotype? Gastroenterology 110:1785-1790, 1996.
7. Mahley RW, Rall SC Jr: Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1:507-537, 2000.
8. Schächter F, Faure-Delanef L, Guénot F, et al: Genetic associations with human longevity at the apo E and ACE loci. Nat Genet 6:29-32, 1994.
9. Brscic E, Bergerone S, Gagnor A, et al: Acute myocardial infarction in young adults: Prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up. Am Heart J 139:979-984, 2000.
10. Lahoz C, Schaefer E, Cupples LA, et al: Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 154:529-537, 2001.
11. Stengard JH, Zerba KE, Pekkanen J, et al: Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 91:265-269, 1995.
12. McCarron MO, Delong D, Alberts MJ: Apo E genotype as a risk factor for ischemic cerebrovascular disease: A meta-analysis. Neurology 53:1308-1311, 1999.
13. Couderc R, Mahieux F, Bailleul S, et al: Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease: A case-control study. Stroke 24:661-664, 1993.
14. DeCarli C, Reed T, Miller BI, et al: Impact of apolipoprotein E epsilon 4 and vascular disease on brain morphology in men from the NHLBI twin study. Stroke 30:1548-1553, 1999.
15. Margaglione M, Seripa D, Gravina C, et al: Prevalence of apolipoprotein E alleles in healthy subjects and survivors of ischemic stroke: An Italian case-control study. Stroke 29:399-403, 1998.
16. Wilson PWF, Schaefer EJ, Larson MG, et al: Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscl Thromb Vasc Biol 16:1250-1255, 1996.
17. Kolovou G, Malakos JS, Hatzaki A, et al: Apolipoprotein E but not angiotensin-converting enzyme polymorphism is associated with myocardial infarction. J Am Coll Cardiol 29:82A, 1997.
18. Hatzaki A, Kolovou G, Hatzivassiliou M, et al: Is there an allelic effect of apolipoprotein E gene polymorphism on plasma lipid parameters in Greek patients with myocardial infarction? Eur Heart J 18(suppl): 64, 1997.
19. Ferrucci L, Guralnik JM, Pahor M, et al: Apolipoprotein Eε2 allele and risk of stroke in the older population. Stroke 28:2410-2416, 1997.
20. Broderick J, Lu M, Jackson C, et al, the NINDS t-PA Stroke Study Group: Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Ann Neurol 49:736-744, 2001.
21. Sklavounou E, Economou-Petersene E, Karadima G, et al: Apolipoprotein E polymorphism in the Greek population. Clin Genet 52:216-218, 1997.
22. James RW, Boemi MG, Giansanti R, et al: Underexpression of the apolipoprotein E4 isoform in an Italian population. Arterioscler Thromb 13:1456-1459, 1993.
23. Bailleul S, Couderc R, Landais V, et al: Direct phenotyping of human apolipoprotein E in plasma: Application to population frequency distribution in Paris (France). Hum Hered 43:159-165, 1993.
24. Humphries SE, Talmud PJ, Hawe E, et al: Apolipoprotein E4 and coronary artery disease in middle-aged men who smoke: A prospective study. Lancet 358:115-119, 2001.
25. Hirono N, Yasuda M, Tanimukai S, et al: Effect of the apolipoprotein Eε4 allele on white matter hyperintensities in dementia. Stroke 31:1263, 2000.
26. Katsuya T, Sato N, Asai T, et al: Association of polymorphism in the promoter region of the apolipoprotein E gene with diastolic blood pressure in normotensive Japanese. Hypertens Res 23:271-275, 2000.
27. Stengard JH, Kardia SL, Tervahauta M, et al: Utility of the predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men aged 65 to 84 years is dependent on context defined by Apo E genotype and area of residence. Clin Genet 56:367-377, 1999.
28. Zaman AG, Helft G, Worthley SG, et al: The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 149:251-266, 2000.
29. Gronholdt M-L, Nordestgaard B, Schroeder T, et al: Ultrasonic echolucent carotid plaques predict future strokes. Circulation 104:68-73, 2001.
30. Slooter AJ, Bots ML, Havekes LM, et al: Apolipoprotein E and carotid artery atherosclerosis: The Rotterdam study. Stroke 32:1947-1952, 2001.
31. Grocott HP, Newman MF, El-Moalem H, et al: Apolipoprotein E genotype differentially influences the proinflammatory and antiinflammatory response to cardiopulmonary bypass. J Thorac Cardiovasc Surg 122:622-623, 2001.
32. Libby P: Molecular bases of the acute coronary syndromes. Circulation 91:2844-2850, 1996.
33. Calara F, Silvestre M, Casanada F, et al: Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E-deficient and LDL receptor-deficient mice. J Pathol 195:257-263, 2001.
34. Mikhailidis DP, Wierzbicki AS (editorial comment): The GREek Atorvastatin and Coronary-heart disease Evaluation (GREACE) study. Curr Med Res Opin 18:215-219, 2002.
35. Papadakis JA, Mikhailidis DP, Winder AF: Lipids and stroke: Neglect of a useful preventive measure? Cardiovasc Res 40:265-271, 1998.
36. Pitsavos CE, Toutouzas PK: Cardiovascular risk factor profile in Greece: Results from the CARDIO 2000 and ATTICA epidemiological studies. Curr Med Res Opin 18:277-283, 2002.
37. Rizos E, Mikhailidis DP: Are high-density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Cardiovasc Res 52:199-207, 2001.
38. Athyros VG, Papageorgiou AA, Mercouris BR, et al: Treatment with Atorvastatin to the National Cholesterol Educational Program Goals versus Usual Care in Secondary Coronary Heart Disease Prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 18:220-228, 2002.
39. Milionis HJ, Rizos E, Mikhailidis DP: Smoking diminishes the beneficial effect of statins: Observations from the landmark trials. Angiology 52:575-587, 2001.
40. Papadakis JA, Ganotakis ES, Jagroop IA, et al: Effect of hypertension, and its treatment, on lipid, lipoprotein (a), fibrinogen and bilirubin levels in patients referred for dyslipidaemia. Am J Hypertens 12:673-681, 1999.
41. Prelevic GM, Kwong P, Byrne DJ, et al: A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 77:945-951, 2002.
42. Milionis HJ, Elisaf MS, Mikhailidis DP: Platelets and lipid-lowering interventions. Platelets 10:357-367, 1999.
43. Jagroop IA, Mikhailidis DP: Angiotensin II can induce and potentiate shape change in human platelets: Effect of losartan. J Human Hypertens 14:581-585, 2000.
44. 1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. J Hum Hypertens 15:203-207, 2001.
45. Tonolo G, Melis MG, Formato M, et al: Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 30:980-987, 2000.
46. Borghi C, Veronesi M, Prandin MG, et al: Statins and blood pressure regulation. Curr Hypertens Rep 3: 281-288, 2001.
47. Glorioso N, Troffa C, Filigheddu F, et al: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 36:1281-1291, 1999.
48. Ibanez AM, Caamano MB, Fernandez MVF, et al: Risk factors for cardiovascular and ischaemic heart disease in a Mediterranean country: Preliminary report of the Zaragoza study (ZACARIS-I). Clin Drug Invest 22:241-251, 2002.
49. Kolovou G, Daskalova D, Mikhailidis DP: Apolipoprotein E polymorphism and atherosclerosis. Angiology 2002; in press.